

## Case Reports

# A Treatable Rare Cause of Progressive Ataxia and Palatal Tremor

Malco Rossi<sup>1\*</sup>, Martin Cesarini<sup>2</sup>, Emilia M. Gatto<sup>2</sup>, Angel Cammarota<sup>1</sup> & Marcelo Merello<sup>1</sup>

<sup>1</sup> Movement Disorders Section and Neurology Department, Raúl Carrea Institute for Neurological Research (FLENI), Buenos Aires, Argentina,

<sup>2</sup> Movement Disorders Section and Neurology Department, Instituto de Neurociencias de Buenos Aires (INEBA), Buenos Aires, Argentina

## Abstract

**Background:** Cerebrotendinous xanthomatosis is a rare autosomal recessive neurometabolic disorder characterized by chronic diarrhea, tendon xanthomas, juvenile cataracts, and neurological symptoms.

**Case Report:** An adult patient with cerebrotendinous xanthomatosis exhibited ataxia and palatal tremor in the absence of tendon xanthomas and cataracts.

**Discussion:** The importance of this case resides on the fact that cerebrotendinous xanthomatosis should be considered as a possible etiology of the syndrome of progressive ataxia with palatal tremor, even in the absence of tendon xanthomas and cataracts. Early diagnosis is critical to the institution of specific treatment with chenodeoxycholic acid.

**Keywords:** Palatal tremor, ataxia, cerebrotendinous xanthomatosis, diagnosis

**Citation:** Rossi M, Cesarini M, Gatto EM, Cammarota A, Merello M. A treatable rare cause of progressive ataxia and palatal tremor. *Tremor Other Hyperkinet Mov.* 2018; 8. doi: 10.7916/D8X07Q2N

\*To whom correspondence should be addressed. E-mail: mrossi@fleni.org.ar

**Editor:** Elan D. Louis, Yale University, USA

**Received:** January 4, 2018 **Accepted:** April 17, 2018 **Published:** May 17, 2018

**Copyright:** © 2018 Rossi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.

**Funding:** None.

**Financial Disclosures:** None.

**Conflict of Interest:** The authors report no conflict of interest.

**Ethics Statement:** All patients that appear on video have provided written informed consent; authorization for the videotaping and for publication of the videotape was provided.

## Introduction

Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive neurometabolic disorder characterized by infantile or early childhood onset of chronic diarrhea, tendon xanthomas, cataracts, and neurological problems, such as behavioral disorders, cognitive impairment, peripheral neuropathy, dystonia, parkinsonism, epilepsy, myoclonus, and progressive cerebellar ataxia, that usually start in the second or third decades of life.<sup>1,2</sup> This disease is caused by mutations in the *CYP27A1* gene that result in decreased production of chenodeoxycholic acid and elevated levels of cholestanol and bile alcohols.<sup>3</sup> Chenodeoxycholic acid is an established treatment that restores metabolic abnormalities and may improve or even prevent neurological deterioration,<sup>4</sup> especially if it is instituted at the early stages of the disease process.<sup>5</sup>

## Case report

A 31-year-old female with no family history of neurological disease or consanguinity was evaluated after a 4-year history of gait instability,

dysarthria, and dysphagia. She had a relevant history of chronic diarrhea at early childhood and depression since 20 years of age. Physical examination disclosed spasmodic-like dysphonia, altered saccadic eye movements, pyramidal signs, proximal and distal muscle wasting in the upper and lower limbs, palatal tremor at low frequency without ear or throat clicks, and mild limb and gait ataxia (Video 1). The Scale for the Assessment and Rating of Ataxia (SARA) score was 15. No tendon xanthomas were present (Figure 1). Electromyography and a nerve conduction study revealed a sensorimotor axonal polyneuropathy. Brain magnetic resonance imaging (MRI) displayed mild cerebellar atrophy and bilateral hyperintensity of the dentate nuclei on fluid-attenuated inversion recovery and T2-weighted images, with a central hypointensity suggestive of calcification (Figure 2A, left and central) and bilateral hyperintensity of the basal ganglia (Figure 2A, right). The olivary nuclei showed a serpiginous abnormal signal, although there was no classic olivary hypertrophy (Figure 2B, left). A brain computed tomography scan showed subtle calcifications in the white matter surrounding the dentate nucleus (Figure 2B, right). Routine work-up studies for ataxia, such

as alpha-fetoprotein, thyroid function and anti-thyroid peroxidase antibodies, celiac disease antibodies (transglutaminase, anti-gliadin, and anti-endomysial), anti-neuronal antibodies, ceruloplasmin, human immunodeficiency virus, cupruria, vitamin B1, B12, and vitamin E levels were normal or negative, except for plasmatic cholesterol levels, which were low (111 mg/dL). CAG repeat determination in the *ATXN1*, *ATXN2*, *ATXN3*, *CACNA1A*, and *ATXN7* genes were negative. Whole-exome sequencing detected two heterozygous variants (c.1183C>T p.(Arg395Cys) and c.1184+1G>A) in the *trans*-phase in the *CYP27A1* gene consistent with a diagnosis of CTX. Cholestanol levels in the serum and tendons were not available for evaluation in our patient. Treatment with chenodeoxycholic acid was started, with improvement of irritability and gait instability (SARA scores slightly improved from 15 to 14 points because of a change in the item that measures stance) and weight gain.

### Discussion

This patient with CTX exhibited palatal tremor and progressive ataxia as the most prominent clinical signs, but without tendon




**Video 1. Cerebrotendinous xanthomatosis revealed by ataxia and palatal tremor in the absence of tendon xanthomas and cataracts.** A 30-year-old female with genetically confirmed cerebrotendinous xanthomatosis showing mild limb and gait ataxia (**Segment 1A and 1B**) and palatal tremor at low frequency (**Segment 1C**).

xanthomas and juvenile cataracts, which are clinical hallmarks of CTX. The frequency of juvenile cataracts and tendon xanthomas in CTX patients averages 88% and 78%, respectively.<sup>6</sup> We cannot rule out the possibility that both problems can appear later in the course of the disease. However, this possibility would be very low, as approximately 75% of CTX patients present with cataracts, often appearing in the first decade of life, whereas xanthomas commonly develop in the second or third decade.<sup>6,7</sup> Large deposits of cholesterol and cholestanol, the 5-alpha-dihydro derivative of cholesterol, are found in virtually every tissue, particularly the Achilles tendons.<sup>7</sup> Low cholesterol and high cholestanol levels in the serum and tendons support the diagnosis of this entity, besides genetic testing.<sup>3,7</sup> Reports of palatal tremor (also referred previously as palatal myoclonus) in genetically confirmed patients with CTX are rare.<sup>8,9</sup> This atypical case combines palatal tremor and ataxia in the absence of the most characteristic clinical features of CTX, thus highlighting the phenotypic variability of this genetic entity. The syndrome of familial or sporadic progressive ataxia and palatal tremor (PAPT) is rare in clinical practice and the cause usually remains uncertain.<sup>10,11</sup> In the sporadic form, brain MRI frequently shows hyperintensity in the inferior olivary nuclei.<sup>10</sup> Even though no classic olivary hypertrophy was found in the patient described here, the olivary nuclei contained a serpiginous abnormal signal suggestive of a “forme fruste” or variant of olivary hypertrophic degeneration. Also, olivary hypertrophy may not be evident with routine MRI sequences, and its presence depends on the stage of olivary degeneration.<sup>12</sup> Despite the subtle olivary nuclei abnormalities, the clinical picture may exceed the classical PAPT syndrome.

A number of differential diagnoses must be considered in patients with progressive ataxia and palatal tremor. For example, the combination of ataxia, palatal tremor, dysphonia resembling spasmodic dysphonia, and dentate calcifications may orient to spinocerebellar ataxia type 20.<sup>13</sup> The hyperintensities observed in the dentate nucleus and the surrounding white matter are common features reported in CTX.<sup>14</sup> Other entities that present with progressive ataxia and palatal



**Figure 1. Imaging of both feet.** Atrophy of the distal foot muscles and absence of xanthomas in the Achilles tendons. There were also no xanthomas in other body parts.



**Figure 2. Brain Magnetic Resonance Imaging.** (A) Flair and T2-weighted images display mild cerebellar atrophy and bilateral hyperintensity of the dentate nuclei on Flair and T2-weighted images with a central hypointensity suggestive of calcification (left and central). Bilateral hyperintensity of the basal ganglia (right). (B) Olivary nuclei with a serpiginous abnormal signal (left). Subtle calcifications in the white matter surrounding the dentate nucleus (right).

**Table 1. Differential Diagnosis of Progressive Ataxia and Palatal Tremor**

Disease Name (Gene)	Inheritance	Main Clinical Features Besides Ataxia and Palatal Tremor	MRI Findings
Spinocerebellar ataxia type 20 (SCA20) <sup>13,17</sup>	AD	Dysphonia resembling spasmodic dysphonia, dysarthria, hypermetric saccades, postural tremor, pyramidal signs	Dentate calcifications and cerebellar atrophy
Spastic paraplegia type 7 or HSP/ATX-SPG7 (SPG7) <sup>18</sup>	AR/AD	Spastic paraparesis, optic atrophy, nystagmus, chronic external ophthalmoplegia-like phenotype, pes cavus, decreased vibratory sense in the lower limbs, scoliosis	Cerebellar and spinal cord atrophy
Neuroferritinopathy or NBIA/CHOR-FTL (FTL) <sup>19,20</sup>	AD	Chorea, oromandibular dyskinesia, dystonia, parkinsonism, dysphagia, psychiatric symptoms, cognitive impairment	Iron accumulation in globus pallidus, caudate, putamen, substantia nigra, red nucleus; cystic basal ganglia changes and pallidal necrosis

**Table 1.** Continued

<b>Disease Name (Gene)</b>	<b>Inheritance</b>	<b>Main Clinical Features Besides Ataxia and Palatal Tremor</b>	<b>MRI Findings</b>
Alexander disease (GFAP) <sup>10,21–23</sup>	AD	Psychomotor regression, spasticity, seizures, pyramidal signs, pseudobulbar signs, macrocephaly	Extensive cerebral white-matter abnormalities with a frontal preponderance, periventricular rim, basal ganglia abnormalities, hydrocephalus
POLG-related disorders (POLG) <sup>24–27</sup>	AR	Dystonia, chorea, myoclonus, tremor, progressive external ophthalmoplegia, seizures, cognitive impairment, psychiatric symptoms, cataracts, optic atrophy, peripheral neuropathy, muscle weakness and atrophy, hypogonadism, stroke-like episodes	Cerebellar atrophy or normal
GM2-gangliosidosis type II or Sandhoff disease (HEXB) <sup>28</sup>	AR	Progressive mental and motor deterioration, macular cherry red spot, blindness, spastic paraparesis, muscular atrophy, fasciculations, dysmorphic features, startle reaction, cardiomegaly, episodic abdominal pain, chronic diarrhea, hepatosplenomegaly	Bilateral symmetric thalamic lesions, hyperintensities in the periventricular, deep, and subcortical white matter, delayed myelination
Progressive ataxia and palatal tremor due to a four-repeat tauopathy <sup>29,30</sup>	Sporadic	Dysarthria, dysphagia, hearing loss, blurring vision, nystagmus	T2 hyperintensities in the bilateral inferior olivary nuclei and cerebellar atrophy
Progressive ataxia and palatal tremor syndrome <sup>10,31,32</sup>	Sporadic (rarely familial)	Dysarthria, nystagmus	T2 hyperintensity and hypertrophy of the bilateral inferior olivary nuclei and cerebellar atrophy
Gluten sensitivity ataxia <sup>33</sup>	Sporadic	Dysarthria	T2 hyperintensity and hypertrophy of the bilateral inferior olivary nuclei and cerebellar atrophy
Multiple system atrophy (cerebellar subtype) <sup>19</sup>	Sporadic	Autonomic failure, action tremor, nystagmus, pyramidal signs, dysarthria, dysphagia	Atrophy of the putamen, middle cerebellar peduncle, or pons. The “hot-cross-bun sign” (cruciform hyperintensity in the pons) in T2-weighted sequences

Abbreviations: AD, Autosomal Dominant; AR, Autosomal Recessive; MRI, Magnetic Resonance Imaging.

tremor are listed in Table 1. A functional disruption in the “Mollaret’s triangle”, formed by the red, dentate, and inferior olivary nuclei has been postulated as the cause of palatal tremor.<sup>15</sup> Presumably, in this patient, the palatal tremor arose because of a disruption of the dentatorubroolivary circuit secondary to the lesions in the olivary nuclei and dentate nuclei.

Neurologists should consider CTX when ataxia, palatal tremor, and dentate nuclei hyperintensities are present, even in the absence of tendon xanthomas and cataracts. Patients with progressive ataxia and palatal tremor should be exhaustively studied, because some cases,

as the one described here, are not sporadic, but of genetic origin and also susceptible to specific treatment.<sup>16</sup> CTX should be added to the differential diagnosis of progressive ataxia and palatal tremor.

## References

1. Degos B, Nadjar Y, Amador M, Lamari F, Sedel F, Roze E, et al. Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood. *Orphanet J Rare Dis* 2016;11:41. doi: 10.1186/s13023-016-0419-x
2. Su CS, Chang WN, Huang SH, Lui CC, Pan TL, Lu CH, et al. Cerebrotendinous xanthomatosis patients with and without parkinsonism:

- clinical characteristics and neuroimaging findings. *Mov Disord* 2010;25:452–458. doi: 10.1002/mds.22979
3. Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. *Orphanet J Rare Dis* 2014;9:179. doi: 10.1186/s13023-014-0179-4
  4. Alhariri A, Hamilton K, Oza V, Cordoro K, Sobreira NL, Malloy M, et al. Clinical report: A patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment. *Am J Med Genet A* 2017;173:2275–2279. doi: 10.1002/ajmg.a.38314
  5. Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. *Clin Neuropharmacol* 2013;36:78–83. doi: 10.1097/WNF.0b013e318288076a
  6. Mignarri A, Gallus GN, Dotti MT, Federico A. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. *J Inher Metab Dis* 2014;37:421–429. doi: 10.1007/s10545-013-9674-3
  7. Cruysberg JR, Wevers RA, van Engelen BG, Pinckers A, van Spreken A, Tolboom JJ. Ocular and systemic manifestations of cerebrotendinous xanthomatosis. *Am J Ophthalmol* 1995;120:597–604. doi: 10.1016/S0002-9394(14)72206-8
  8. Lagarde J, Roze E, Apartis E, Pothalil D, Sedel F, Couvert P, et al. Myoclonus and dystonia in cerebrotendinous xanthomatosis. *Mov Disord* 2012;27:1805–1810. doi: 10.1002/mds.25206
  9. Szlago M, Gallus GN, Schenone A, Patiño ME, Sfaelo Z, Rufa A, et al. The first cerebrotendinous xanthomatosis family from Argentina: a new mutation in CYP27A1 gene. *Neurology* 2008;70:402–404. doi: 10.1212/01.wnl.0000280460.28039.3d
  10. Samuel M, Torun N, Tuite PJ, Sharpe JA, Lang AE. Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. *Brain* 2014;127:1252–1268. doi: 10.1093/brain/awh137
  11. Zuzuarregui JR, Frank SA. Progressive ataxia and palatal tremor. *JAMA Neurol* 2015;72:1195. doi: 10.1001/jamaneurol.2015.1114
  12. Goyal M, Versnick E, Tuite P, Cyr JS, Kucharczyk W, Montanera W, et al. Hypertrophic olivary degeneration: metaanalysis of the temporal evolution of MR findings. *AJNR Am J Neuroradiol* 2000;21:1073–1077.
  13. Knight MA, Gardner RJ, Bahlo M, Matsuura T, Dixon JA, Forrest SM, et al. Dominantly inherited ataxia and dysphonia with dentate calcification: spinocerebellar ataxia type 20. *Brain* 2014;127:1172–1181. doi: 10.1093/brain/awh139
  14. Mignarri A, Dotti MT, Federico A, De Stefano N, Battaglini M, Grazzini I, et al. The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression. *J Neurol* 2017;264:862–874. doi: 10.1007/s00415-017-8440-0
  15. Deuschl G, Toro C, Valls-Solé J, Zeffiro T, Zee DS, Hallet M. Symptomatic and essential palatal tremor. I. Clinical, physiological and MRI analysis. *Brain* 1994;117:775–788. doi: 10.1093/brain/117.4.775
  16. Jinnah HA, Albanese A, Bhatia KP, Cardoso F, Da Prat G, de Koning TJ, et al. Treatable inherited rare movement disorders. *Mov Disord* 2018;33:21–35. doi: 10.1002/mds.27140
  17. Rossi M, Perez-Lloret S, Cerquetti D, Merello M. Movement disorders in autosomal dominant cerebellar ataxias: a systematic review. *Mov Disord Clin Pract* 2014;1:154–160. doi: 10.1002/mdc3.12042
  18. Gass J, Blackburn PR, Jackson J, Macklin S, van Gerpen J, Atwal PS. Expanded phenotype in a patient with spastic paraplegia 7. *Clin Case Rep* 2017;5:1620–1622. doi: 10.1002/ccr3.1109
  19. Wills AJ, Sawle GV, Guilbert PR, Curtis AR. Palatal tremor and cognitive decline in neuroferritinopathy. *J Neurol Neurosurg Psychiatry* 2002;73:91–92. doi: 10.1136/jnnp.73.1.91
  20. Chinnery PF, Curtis AR, Fey C. Neuroferritinopathy in a French family with late onset dominant dystonia. *J Med Genet* 2003;40:e69. doi: 10.1136/jmg.40.5.e69
  21. Kulkarni PK, Muthane UB, Taly AB, Jayakumar PN, Shetty R, Swamy HS. Palatal tremor, progressive multiple cranial nerve palsies, and cerebellar ataxia: a case report and review of literature of palatal tremors in neurodegenerative disease. *Mov Disord* 1999;14:689–693. doi: 10.1002/1531-8257(199907)14:4<689::AID-MDS1022>3.0.CO;2-8
  22. Schwankhaus JD, Parisi JE, Gullledge WR, Chin L, Currier RD. Hereditary adult-onset Alexander's disease with palatal myoclonus, spastic paraparesis, and cerebellar ataxia. *Neurology* 1995;45:2266–2271. doi: 10.1212/WNL.45.12.2266
  23. Sebesto JR, van Gerpen JA. Teaching video neuroimages: palatal tremor in adult-onset Alexander disease. *Neurology* 2016;86:e252. doi: 10.1212/WNL.0000000000002763
  24. Mongin M, Delorme C, Lenglet T, Jardel C, Vignal C, Roze E. Progressive ataxia and palatal tremor: think about POLG mutations. *Tremor Other Hyperkinet Mov* 2016;6. doi: 10.7916/D86M36RK
  25. Nicastro N, Ranza E, Antonarakis SE, Horvath J. Pure progressive ataxia and palatal tremor (PAPT) associated with a new polymerase gamma (POLG) mutation. *Cerebellum* 2016;15:829–831. doi: 10.1007/s12311-015-0749-6
  26. Rossi M, Medina Escobar A, Radrizzani M, Tenenbaum S, Perandones C, Merello M. Dystonia in a patient with autosomal-dominant progressive external ophthalmoplegia type 1 caused by mutation in the POLG gene. *Mov Disord Clin Pract* 2015;4:266–269. doi: 10.1002/mdc3.12397
  27. Synofzik M, Srulijes K, Godau J, Berg D, Schöls L. Characterizing POLG ataxia: clinics, electrophysiology and imaging. *Cerebellum* 2012;11:1002–1011. doi: 10.1007/s12311-012-0378-2
  28. Pretegianni E, Rosini F, Federighi P, Cerase A, Dotti MT, Rufa A. Pendular nystagmus, palatal tremor and progressive ataxia in GM2-gangliosidosis. *Eur J Neurol* 2015;22:e67–9. doi: 10.1111/ene.12661
  29. Mari Z, Halls A, Vortmeyer A, Zhukareva V, Uryu K, Lee V.M.-Y, et al. Clinico-pathological correlation in progressive ataxia and palatal tremor: a novel tauopathy. *Mov Disord Clin Pract* 2014;1:50–56. doi: 10.1002/mdc3.12014
  30. Gao AF, Faust-Socher A, Al-Murshed M, Del Bigio MR, Lang AE, Munoz DG. Progressive ataxia and palatal tremor: two autopsy cases of a novel tauopathy. *Mov Disord* 2017;32:1465–1473. doi: 10.1002/mds.27074
  31. Tilikete C, Desestret V. Hypertrophic olivary degeneration and palatal or oculopalatal tremor. *Front Neurol* 2017;8:302. doi: 10.3389/fneur.2017.00302
  32. Korpela J, Joutsa J, Rinne JO, Bergamn J, Kaasinen V. Hypermetabolism of olivary nuclei in a patient with progressive ataxia and palatal tremor. *Tremor Other Hyperkinet Mov* 2015;5. doi: 10.7916/D8PV6JMT
  33. Kheder A, Currie S, Romanowski C, Hadjivassiliou M. Progressive ataxia with palatal tremor due to gluten sensitivity. *Mov Disord* 2012;27:62–63. doi: 10.1002/mds.23987